AtriCure (ATRC)
(Delayed Data from NSDQ)
$29.02 USD
+0.21 (0.73%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $29.03 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Brokerage Reports
0 items in cart
AtriCure, Inc. [ATRC]
Reports for Purchase
Showing records 1 - 20 ( 59 total )
Company: AtriCure, Inc.
Industry: Medical - Products
Optimized Entry and Exit Levels for ATRC 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: AtriCure, Inc.
Industry: Medical - Products
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
We are dropping coverage due to the realignment of the Med Tech research team.
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
Solid Start, Investments to Bolster Growth in 2H13; Buy
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
1Q13 MedTech Preview: ALGN ICUI TRIB CRY CPTS ATEC RTIX SLTM VOLC ATRC (Part 1)
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
Healthcare - 1Q 2013: Quarterly Medical Technology Trading & Acquisition Update
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
2013 Guidance Inline -New CEO Plan Sound, Should Help Stock; Buy
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
4Q12 Preview: 4Q Consistent with Preannouncement; Initial Guidance Inline
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
Equity Raise Sooner Than Anticipated, but Needed; Updating Model
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
Healthcare -4Q 2012: Quarterly Medical Technology Trading & Acquisition Update
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
Small Bump in Road, But Now At Least Someone?s Behind the Wheel; Buy
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
3Q Preview: Business Doing Fine Despite Management Uncertainty
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
New CEO Around the Corner? Should be Positive for Stock - Maintain Buy
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
CEO Departure a Shock - PT Down on NT Uncertainty, Business Undervalued
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M